Photocure ASA

Board/Management Information • Apr 28, 2017

Photocure Appoints Three New Members to its Board of Directors

Photocure Appoints Three New Members to its Board of Directors

Dr. Jan Hendrik Egberts - Board Chairman

Dr. Johanna Holldack

Ms. Gwen Melincoff

Oslo, Norway April, 28, 2017: Photocure ASA (OSE:PHO), a

specialty pharmaceutical company and world leader in

photodynamic technology for treatment of bladder cancer,

today announced the appointment of Jan Hendrik Egberts,M.D.,

Johanna Holldack,M.D. and Gwen Melincoff to its board of

directors with Dr. Egberts as the new board chairman.

Kjetil Hestdal, President and Chief Executive Officer of

Photocure said, "We are pleased to welcome Jan Hendrik

Egberts, Johanna Holldack and Gwen Melincoff to Photocure's

Board of Directors. Their extensive life science experience

and strong international relationships will be valuable as

we plan and execute our development and commercialization

plans. The successful execution of our expansion in the

U.S. market is a key focus and their contribution to our

Board will benefit us greatly."

Dr. Egberts has over 25 years of experience in the

pharmaceutical and medical devices sector. Currently, Dr

Egberts serves as the Managing Partner of Veritas

Investments, a private investment company focused on

minority and controlling investments in healthcare

companies. Dr Egberts gained his medical degree from Erasmus

University Medical School in the Netherlands and pursued the

clinical part of his medical training at Harvard Medical

School. Dr Egberts also obtained an MBA from Stanford

University. After Stanford, he joined McKinsey & Co. as a

strategic consultant in New York. Dr Egberts subsequently

held various business development and general management

positions of increasing responsibility in the USA at Merck &

Co. and Johnson & Johnson. While at J&J, he initiated and

subsequently led the leveraged buyout of the BARRIER

surgical drapes and gowns business from J&J and the

subsequent merger with Mölnlycke Health Care. Thereafter, he

served as Senior Advisor, Healthcare Investments for 3i, the

private equity firm. Dr Egberts then became CEO of OctoPlus,

a publicly traded specialty pharmaceutical company in the

Netherlands. OctoPlus was subsequently acquired by Dr Reddy

Laboratories. After this, Dr Egberts joined Agendia, a

molecular diagnostics company, initially as board member and

subsequently full time as interim CEO. Dr Egberts also has

held over 15 executive and non-executive supervisory board

positions in the U.S.A. and various European countries.

Dr. Holldack has international operational experience from

pharma companies, including clinical trials, drug approvals,

IPOs and licensing. She has also managed several mergers and

acquisitions. In addition, Dr. Holldack has venture capital

experience from Swiss-based Aravis Venture where she was a

partner for 5 years. Her industry career spans over 20

years, during which she held key positions in both start-up

and large pharma companies. Her experience includes

management and executive positions at Behringwerke, Chiron,

MediGene, Borean Pharma, Telormedix and Trethera

Corporation. She is chairman of Amal Therapeutics. In

Telormedix she gained experience within the field of bladder

cancer, something highly relevant for Photocure. Dr.

Holldack has a medical degree from Georg-August-University

in Gottingen, Germany and is a Board Certified pediatrician.

In addition, she has held positions as an assistant

professor at the University of Essen, research fellow for

the Deutsche Krebshilfe and a research associate at Harvard

Medical School.

Ms. Melincoff has over 25 years of leadership experience in

the biotechnology and pharmaceutical industries. Her

experience has spanned public and private company boards,

venture financing, business development, licensing, mergers

and acquisitions, research operations, marketing, product

management and project management. From August 2014 to

September 2016, she served as Vice President of Business

Development at BTG International Inc. From September 2004 to

the December 2013, Ms. Melincoff was Senior Vice President

of Business Development at Shire Pharmaceuticals.

Additionally, she led the Strategic Investment Group (SIG),

Shire's $50MM corporate venture fund which was started in

2010. During her tenure, she was involved in numerous

licenses, product divestments, co-promotion and

collaboration agreements, and mergers and acquisitions.

Melincoff was named a "Top Women in Biotech 2013" by Fierce

Biotech as well as being named to the Powerlist 100 of

Corporate Venture Capitalist in 2012 and 2013. Ms.

Melincoff has a B.S in Biology, a Master's of Science in

Management, and has attained the designation of the

Certified Licensing Professional (CLP[TM]).

About Photocure ASA

Photocure, headquartered in Oslo Norway, is a specialty

pharmaceutical company and world leader in photodynamic

technology. As a commercial stage company focused on the

urology market, Photocure's proprietary technology provides

improved detection and management of bladder cancer. Our

aim is to provide solutions which can improve health

outcomes for patients worldwide. Photocure is listed on the

Oslo Stock Exchange (OSE: PHO). Information about Photocure

is available at www.photocure.com.

For more information, please contact:

Kjetil Hestdal

President and CEO,

Tel: + 47 91319535

Email: kh@photocure.com

Erik Dahl

Chief Financial Officer

Tel: +47 450 55 000

Email: ed@photocure.no